EVALUATION OF THE EFFECT OF ADEMOL ON THE DYNAMICS OF NEURON-SPECIFIC ENOLASE IN TRAUMATIC BRAIN INJURY IN RATS

Area of Science:

• Neuroscience
• Pharmacology
• Traumatology

Background:

• Modern medicine seeks effective neuroprotective therapies for neuronal damage.
• Traumatic brain injury (TBI) presents significant challenges in treatment and recovery.
• Understanding pathophysiological cascades is crucial for developing new therapeutic strategies.

Purpose of the Study:

• To evaluate the neuroprotective efficacy of ademol, an adamantane derivative, in an experimental TBI model.
• To compare the effects of ademol with amantadine sulfate and a saline control on neuron-specific enolase (NSE) levels.
• To assess the therapeutic potential of ademol in mitigating neuronal damage post-TBI.

Main Methods:

• An acute traumatic brain injury (TBI) model was established in rats.
• Animals received intravenous (IV) administration of ademol (2 mg/kg), amantadine sulfate (5 mg/kg), or 0.9% NaCl every 12 hours for 8 days.
• The level of neuron-specific enolase (NSE) was measured to assess neuroprotection.

Main Results:

• Both ademol and amantadine sulfate significantly reduced elevated NSE levels in rats with TBI compared to the control group.
• Ademol (2 mg/kg IV) reduced NSE levels by an average of 52.1%, while amantadine sulfate (5 mg/kg IV) reduced them by 38.2%.
• Ademol demonstrated a superior neuroprotective effect, outperforming amantadine sulfate by 22.5% in preventing NSE level increases.

Conclusions:

• Ademol exhibits potent neurocytoprotective properties against experimental traumatic brain injury.
• The neuroprotective effect of ademol is more pronounced than that of amantadine sulfate in this TBI model.
• Ademol represents a promising therapeutic agent for managing neuronal damage following head injuries.